A detailed history of Candriam S.C.A. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 95,821 shares of KYMR stock, worth $4.13 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
95,821
Previous 238,165 59.77%
Holding current value
$4.13 Million
Previous $7.11 Million 36.21%
% of portfolio
0.03%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$30.16 - $52.4 $4.29 Million - $7.46 Million
-142,344 Reduced 59.77%
95,821 $4.54 Million
Q2 2024

Aug 05, 2024

SELL
$29.85 - $39.42 $2.69 Million - $3.55 Million
-90,137 Reduced 27.46%
238,165 $7.11 Million
Q1 2024

May 03, 2024

SELL
$22.9 - $43.57 $343,500 - $653,550
-15,000 Reduced 4.37%
328,302 $13.2 Million
Q4 2023

Feb 14, 2024

SELL
$10.97 - $26.84 $1.59 Million - $3.89 Million
-145,004 Reduced 29.7%
343,302 $8.74 Million
Q2 2023

Aug 08, 2023

SELL
$22.4 - $34.92 $519,007 - $809,096
-23,170 Reduced 4.53%
488,306 $11.2 Million
Q4 2022

Feb 13, 2023

SELL
$19.57 - $30.92 $746,438 - $1.18 Million
-38,142 Reduced 6.94%
511,476 $12.8 Million
Q3 2022

Nov 10, 2022

BUY
$20.91 - $34.27 $1.67 Million - $2.73 Million
79,758 Added 16.97%
549,618 $12 Million
Q2 2022

Aug 03, 2022

BUY
$14.13 - $42.55 $779,227 - $2.35 Million
55,147 Added 13.3%
469,860 $9.25 Million
Q1 2022

May 13, 2022

BUY
$35.3 - $64.68 $419,858 - $769,303
11,894 Added 2.95%
414,713 $17.6 Million
Q4 2021

Feb 10, 2022

BUY
$49.91 - $65.56 $390,695 - $513,203
7,828 Added 1.98%
402,819 $25.6 Million
Q3 2021

Nov 09, 2021

SELL
$47.8 - $66.66 $764,800 - $1.07 Million
-16,000 Reduced 3.89%
394,991 $23.2 Million
Q2 2021

Jul 20, 2021

BUY
$31.08 - $51.95 $12.8 Million - $21.4 Million
410,984 Added 5871200.0%
410,991 $19.9 Million
Q1 2021

Apr 29, 2021

BUY
$35.64 - $85.46 $249 - $598
7 New
7 $0

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.36B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.